This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through March 4, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Accelerate Diagnostics (AXDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Accelerate Diagnostics (AXDX) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Accelerate Diagnostics (AXDX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
How Accelerate Diagnostics (AXDX) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Accelerate Diagnostics (AXDX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Will Accelerate Diagnostics (AXDX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Accelerate Diagnostics (AXDX) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Accelerate Diagnostics (AXDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Accelerate Diagnostics (AXDX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 5.13% and -27.97%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Accelerate Diagnostics (AXDX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Accelerate Diagnostics (AXDX) Jumps: Stock Rises 9.4%
by Zacks Equity Research
Accelerate Diagnostics (AXDX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 5.00% and -33.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Accelerate Diagnostics (AXDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 6.98% and -17.57%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Accelerate Diagnostics (AXDX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Accelerate Diagnostics (AXDX) Q4 Earnings Expected to Decline
by Zacks Equity Research
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Accelerate Diagnostics (AXDX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 6.82% and -53.05%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Accelerate Diagnostics (AXDX) Q3 Earnings Expected to Decline
by Zacks Equity Research
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Accelerate Diagnostics (AXDX) Surges: Stock Moves 6% Higher
by Zacks Equity Research
Accelerate Diagnostics (AXDX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -16.22% and -22.03%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Moving Average Crossover Alert: Accelerate Diagnostics, Inc. (AXDX)
by Zacks Equity Research
Moving Average Crossover Alert: Accelerate Diagnostics, Inc. (AXDX)
Accelerate Diagnostics (AXDX) in Focus: Stock Moves 6.7% Higher
by Zacks Equity Research
Accelerate Diagnostics (AXDX) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
Accelerate Diagnostics (AXDX) In Focus: Stock Rises 5.1%
by Zacks Equity Research
Accelerate Diagnostics (AXDX) was a big mover last session, as the company saw its shares rise more than 5% on the day.
Here's Why You Can Buy Quest Diagnostics Stock Right Now
by Zacks Equity Research
Quest Diagnostics Incorporated (DGX) is on a healthy growth trajectory of late.
Illumina Offers FDA-Approved NGS Cancer Companion Test Kit
by Zacks Equity Research
Illumina, Inc. (ILMN) recently announced that its FDA-approved next-generation sequencing (NGS) -- Extended RAS Panel has met the Current Colorectal Cancer Guidelines.
Lantheus Holdings at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Lantheus Holdings, Inc. (LNTH), based in North Billerica, U.S., scaled a new 52-week high of $17.85 on Jun 30, eventually closing a bit lower at $17.65.
Envision Healthcare (EVHC) Acquires Anesthesia Associates
by Zacks Equity Research
Envision Healthcare Corporation (EVHC), recently announced that it has acquired Connecticut based anesthesia physician group practice, Anesthesia Associates of New London, P.C.
Boston Scientific Rides on New Growth Plans amid Headwinds
by Zacks Equity Research
On Jun 29 2017, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).